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30 years of step-by-step development2 were necessary
to get access to the tip-to-tip heparin-coated CPB circuit
that allowed, first, partial and, later, total CPB3 with low
systemic heparin levels similar to those used in vascu-
lar surgery (ACT > 180 seconds). Even though a num-
ber of studies have demonstrated reduced blood loss
and transfusion requirements after CPB with heparin-
coated equipment and low systemic heparinization,4,5
this issue remains the subject of controversy. 
In parallel, many groups documented that heparin
surface coating of perfusion equipment reduced the
perfusion-induced inflammatory response.6 These find-
ings may be less striking in the clinical setting with full
systemic heparinization, because of the significant
noise level resulting from cardiotomy suction7 and
other ancillary equipment. However, increasing evi-
dence shows that heparin–coated perfusion equipment
is beneficial, despite full systemic heparinization.
Wahba and colleagues8 have demonstrated significant
reduction of transoxygenator/heat exchanger pressure
gradients for various heparin-coated devices as com-
pared with uncoated devices during routine cardiac
surgery. These findings suggest that the pressures
between the main pump and the oxygenator/heat
exchanger structure often reach critical levels in current
clinical practice in which uncoated perfusion equip-
ment is used. This phenomenon usually is unnoticed
because the arterial pressure is not usually measured
anterior to the oxygenator/heat exchanger structure.
Obviously, routine CPB is still far from perfect.
Once more, Øvrum and colleagues have provided an
important piece of work in this setting. Their most
recent study9 involves 1336 patients undergoing routine
coronary bypass with either Duraflo II (Baxter
Healthcare Corp, Bentley Laboratories Division, Irvine,
Calif) or Carmeda BioActive Surface (CBAS;
Medtronic Inc, Minneapolis, Minn) heparin-coated
CPB equipment with low systemic heparinization (ACT
> 250 seconds). The 2 heparin coatings studied have
very different histories, are chemically different, and
are bonded differently. Baseline patient parameters and
outcomes look similar for the 2 patient groups ana-
lyzed. The patients with Duraflo II–coated CPB equip-
ment required less systemic heparin to maintain the tar-
get ACT than did the patients with CBAS-coated CPB
T he first article on heparin surface bonding was pub-lished in 1963 by Gott, Whiffen, and Datton.1 At
that time, the development of blood-exposed surfaces
with improved thromboresistance was of prime interest.
In those days, device occlusion during cardiopulmonary
bypass (CPB) was a current problem. The presence of a
shunt line that allows the arterial filter to be bypassed in
most CPB circuits is still a testament to this major
weakness of perfusion. Fortunately, in the early days
the arterial filters tended to thrombose before the heat
exchangers and oxygenators, and bypassing them usu-
ally salvaged the procedure. However, increasing
awareness of this problem led to the development of
more thromboresistant arterial filters with a variety of
heparin surface coatings. The success of these efforts
opened the door for systematic application of heparin
surface coatings for filter screens at various positions in
the CPB circuit. Routine clinical use of heparin-coated
components was thus established. The practice
remained unrecognized for many years because CPB
appeared to be extremely safe in conjunction with full
systemic heparinization as defined by an activated
coagulation time (ACT) of more than 480 seconds. 
Use of heparin-coated equipment for perfusion with
low or no systemic heparinization again goes back to
Gott, who introduced the Gott shunt for bypassing
blood during repair of aneurysms of the descending tho-
racic aorta. This approach, which was adopted by many
surgeons, provided evidence that perfusion devices did
not require full systemic heparinization if their design
and surface properties were adequate. However, almost
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temic heparinization (eg, bleeding, homologous trans-
fusion, transfusion-related infection with regularly
updated additional microorganisms). Hence, although
the CPB philosophy selected for a specific patient (full
versus low systemic heparinization) is a tradeoff, it
becomes more and more apparent that, effectively,
there is no free ride! 
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equipment. Interestingly enough, patients in the
Duraflo II group also required less protamine for neu-
tralization of circulating heparin than did patients in the
CBAS group. The authors suggest that heparin leakage
from the Duraflo II coating, which is more common
than leakage from the CBAS coating, can explain this
finding. However, if free heparin originating from the
coating would have to be neutralized together with
injected heparin, thus completing the total amount of
circulating heparin necessary to reach a certain target
ACT, one would expect to see no difference for prota-
mine requirements between the 2 groups analyzed.
Alternatively, a higher rate of antithrombin III adsorp-
tion onto the CBAS coating can explain higher require-
ments for both circulating heparin and then protamine
as compared with the Duraflo II group. 
Other mechanisms are involved as well, but this the-
oretical discussion should not divert our attention from
the fact that Øvrum and colleagues9 have operated on a
substantial number of patients (1336) who underwent
routine coronary bypass grafting with low systemic
heparinization and no oxygenator obstruction. Their
achievements include 4.6 ± 1.3 distal anastomoses per
patient, at least 1 internal thoracic artery anastomosis in
99.3% of the patients, homologous transfusions in only
4.3% of the patients, and a hospital mortality of 0.3%
(4/1336 patients)! If this was the standard of care on
January 1, 2000, the rest of us doing CPB operations,
as well as those involved in blood banking, are facing a
major challenge.
Of course, one has to be aware of the disadvantages
of perfusion with low systemic heparinization despite
the use of heparin-coated equipment (eg, potential for
device occlusion, stroke) and the technical hints to
avoid them.3 However, to give this approach a fair trial,
one must also consider the disadvantages of full sys-
